Tucidinostat Combined with Bortezomib, Liposomal Doxorubicin, and Dexamethasone in Multiple Myeloma Treatment
The C-PDD regimen showed efficacy in RRMM, including bortezomib-refractory disease and EME patients. The optimal dose and combination need to be explored in the future.
Authors
- Xiaoguang Lei (ORCID: https://orcid.org/0000-0002-0380-8035)
- Xiao‐Jun Huang (ORCID: https://orcid.org/0000-0002-2145-6643)
- Mingdi Wang
- Jingru Bi
- Jin Lu (ORCID: https://orcid.org/0000-0001-5791-2252)
- Huixia Guo (ORCID: https://orcid.org/0000-0001-9660-9520)
- Liru Wang (ORCID: https://orcid.org/0009-0007-3465-3279)
- Yang Liu (ORCID: https://orcid.org/0000-0002-8471-8460)
- Xuelin Dou (ORCID: https://orcid.org/0000-0001-7040-9272)
- Wen Lei (ORCID: https://orcid.org/0000-0002-7649-2449)
- Ruqi Liang
Institutions
- King University (US)
- Capital Medical University (CN)
- Peking University (CN)
- Peking University People's Hospital (CN)
- Peking University Shougang Hospital (CN)
Publication Details
- Journal
- Acta Haematologica
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1159/000545709
- Citations
- 1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77